Boc-d-beta-高丝氨酸 | 749208-35-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: Boc-d-beta-高丝氨酸
• 英文名称: (R)-3-((tert-Butoxycarbonyl)amino)-4-hydroxybutanoic acid
• 英文别名: (3R)-4-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid
• CAS: 749208-35-3
• 化学式: C₉H₁₇NO₅
• 分子量: 219.238
• InChiKey: PRSIONPHFVWSKD-ZCFIWIBFSA-N

物化性质

• 沸点：
  416.9±40.0 °C(Predicted)
• 密度：
  1.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  95.9
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  Boc-d-beta-高丝氨酸 在 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 methyl (R)-3-((tert-butoxycarbonyl)amino)-4-((methylsulfonyl)oxy)butanoate
  参考文献：
  名称：

  Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors

  摘要：

  We previously reported on a series of cyclohexanediamine derivatives as highly potent factor Xa inhibitors. Herein, we describe the modification of the spacer moiety to discover an alternative scaffold. Ethylenediamine derivatives possessing a substituent at the C1 position in S configuration and phenylenediamine derivatives possessing a substituent at the C5 position demonstrated moderate to strong anti-fXa activity. Further SAR studies led to the identification of compound 30h which showed both good in vitro activity (fXa IC50 = 2.2 nM, PTCT2 = 3.9 mu M) and in vivo antithrombotic efficacy. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.132
• 作为产物：
  描述：

  叔丁氧羰基-D-天冬氨酸 4-苄酯 在 sodium tetrahydroborate 、 palladium 10% on activated carbon 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 生成 Boc-d-beta-高丝氨酸
  参考文献：
  名称：

  Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors

  摘要：

  We previously reported on a series of cyclohexanediamine derivatives as highly potent factor Xa inhibitors. Herein, we describe the modification of the spacer moiety to discover an alternative scaffold. Ethylenediamine derivatives possessing a substituent at the C1 position in S configuration and phenylenediamine derivatives possessing a substituent at the C5 position demonstrated moderate to strong anti-fXa activity. Further SAR studies led to the identification of compound 30h which showed both good in vitro activity (fXa IC50 = 2.2 nM, PTCT2 = 3.9 mu M) and in vivo antithrombotic efficacy. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.132

文献信息

• [EN] BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS AND USES THEREOF<br/>[FR] ACIDES BÊTA-AMINÉS SUBSTITUÉS EN BÊTA ET ANALOGUES À UTILISER EN TANT QU'AGENTS DE CHIMIOTHÉRAPIE ET LEURS UTILISATIONS
  申请人：QUADRIGA BIOSCIENCES INC

  公开号：WO2017024009A1

  公开（公告）日：2017-02-09

  β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.

  β-取代β-氨基酸，β-取代β-氨基酸衍生物，β-取代β-氨基酸类似物和（生物）同位素以及它们作为化疗药物的用途被披露。β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物和（生物）同位素是选择性LAT1/4F2hc底物，并在表达LAT1/4F2hc转运蛋白的肿瘤中表现出快速摄取和保留。还披露了合成β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物的方法以及使用这些化合物治疗癌症的方法。β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物在表达LAT1/4F2hc转运蛋白的肿瘤细胞中表现出选择性摄取，并在体内给予受试者后在癌细胞中积累。β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物和（生物）同位素对几种肿瘤类型表现出细胞毒性。
• [EN] MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES<br/>[FR] INHIBITEURS MACROCYCLIQUES DE PEPTIDYLARGININE DÉIMINASES
  申请人：GILEAD SCIENCES INC

  公开号：WO2021222353A1

  公开（公告）日：2021-11-04

  The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

  本公开涉及用于治疗与肽精氨酸脱亚氨酶（PADs）相关的疾病的新化合物，例如肽精氨酸脱亚氨酶类型4（PAD4）。本公开还涉及用于制备这些化合物的过程和中间体，使用这些化合物的方法以及包含所述化合物的药物组合物。
• Benzamidine derivatives
  申请人：AJINOMOTO CO., INC

  公开号：US20010056123A1

  公开（公告）日：2001-12-27

  Benzamidine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an effect of inhibiting activated blood-coagulation factor X, and they are useful as agents for preventing or treating various diseases caused by thrombi or emboli. 1

  以下公式的苯甲酰胺衍生物、类似物及其药用盐已提供。这些化合物具有抑制活化血凝因子X的作用，可用作预防或治疗由血栓或栓塞引起的各种疾病的药物。
• [EN] CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASEV INHIBITORS<br/>[FR] COMPOSES GLUTARAMIDE A SUBSTITUTION CYCLOPENTILE UTILISES COMME INHIBITEURS DE L'ENDOPEPTIDASE
  申请人：PFIZER LTD

  公开号：WO2004056750A1

  公开（公告）日：2004-07-08

  The invention relates to NEP inhibitors for treating cardiovascular disorders. Preferred NEP inhibitors are compounds of formula (I) wherein R1 is C,-C6alkyl, Ci-C6alkoxyC,­C3alkyl or C,-C6alkoxyC,-C6alkoxyC,-C3alkyl; R2 is hydrogen or C,-C6alkyl; L is a three 5 atom linkage selected from -CH2-X-CH2- and -CH2-CH2-X- where the right hand side of the linkage is attached to R3 and where X is oxygen, sulfur or methylene; R3 is phenyl or aromatic heterocyclyl, either of which may be independently substituted by one or more groups selected from: C1-C6alkyl, halo, haloC,-C6alkyl, C,-C6alkoxy, haloC1-C6alkoxy, C1-­C6alkylthio, haloC,-C6alkylthio and nitrile; and R4 and R5 are either both hydrogen, or one of R4 and R5 is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen.

  该发明涉及NEP抑制剂用于治疗心血管疾病。首选的NEP抑制剂是具有以下结构的化合物(I)：其中R1为C1-C6烷基，C1-C6烷氧基C1-C3烷基或C1-C6烷氧基C1-C6烷氧基C1-C3烷基；R2为氢或C1-C6烷基；L为从-CH2-X-CH2-和-CH2-CH2-X-中选择的三个原子连接，其中连接的右侧连接到R3，X为氧、硫或亚甲基；R3为苯基或芳香杂环基，两者中的任何一个都可以独立地被一个或多个来自以下群的基取代：C1-C6烷基，卤素，卤代C1-C6烷基，C1-C6烷氧基，卤代C1-C6烷氧基，C1-C6烷基硫基，卤代C1-C6烷基硫基和腈基；R4和R5要么都是氢，要么R4和R5中的一个是氢，另一个是在患者体内被氢替代的生物可解脂基。
• Benzamidine derivative
  申请人：AJINOMOTO CO., INC.

  公开号：US20020107290A1

  公开（公告）日：2002-08-08

  Benzamidine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an effect of inhibiting activated blood-coagulation factor X, and they are useful as agents for preventing or treating various diseases caused by thrombi or emboli. 1

  提供以下公式的苯甲酰胺衍生物，其类似物和药学上可接受的盐。这些化合物具有抑制活化的血凝因子X的作用，并且它们可用作预防或治疗由血栓或栓塞引起的各种疾病的药物。1